Syzalterin is primarily used in pharmaceutical research for its potential neuroprotective properties. It has shown promise in early-stage studies targeting neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease by modulating specific neuronal signaling pathways. Its ability to cross the blood-brain barrier enhances its suitability for central nervous system therapies. Additionally, Syzalterin exhibits anti-inflammatory and antioxidant activities, making it a candidate for development in treatments aimed at reducing oxidative stress in neural tissues. Ongoing research explores its efficacy in combination therapies and its long-term safety profile for therapeutic use.